We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

000559:SZSEWanxiang Qianchao Co.,Ltd. Analysis

Data as of 2026-05-24 - not real-time

CN¥17.91

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Wanxiang Qianchao is trading above its short‑term moving average while still lagging behind the long‑term trend, and the MACD has turned bullish with a positive histogram, suggesting momentum may be picking up. The RSI sits in a neutral zone, indicating the stock is not yet overbought, and daily volume is on an upward trajectory, reinforcing the technical optimism. Current price is holding near a clear support area and is approaching a resistance ceiling that has capped recent rallies, while market sentiment is in an extreme greed phase, which could fuel short‑term buying pressure. However, the company’s revenue has been contracting and margins remain thin, painting a challenging operating backdrop. Valuation metrics are stretched, with a trailing PE far above the market average and a DCF‑derived fair value that is dramatically lower than the market price, signaling significant overvaluation. The dividend payout is modest and supported by cash, yet the balance sheet carries a high debt load that could constrain future flexibility. Volatility is elevated, and while beta is on the lower side, the combination of cyclical sector exposure and Chinese regulatory dynamics adds layers of risk. Overall, the stock exhibits a blend of technical upside potential but fundamental headwinds that temper enthusiasm.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD and rising volume
  • Proximity to technical support
  • High valuation relative to DCF

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Revenue contraction and thin margins
  • Elevated PE and overvaluation
  • Sustained dividend with moderate payout ratio

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Significant overvaluation versus intrinsic value
  • High debt burden and limited cash flow cushion
  • Cyclical exposure and regulatory uncertainty in China

Key Metrics & Analysis

Financial Health

Revenue Growth-19.80%
Profit Margin7.79%
P/E Ratio59.7
ROE10.71%
ROA2.79%
Debt/Equity91.50
P/B Ratio6.8
Op. Cash FlowCN¥1.3B
Free Cash FlowCN¥1.1B

Technical Analysis

TrendBullish
RSI56.4
SupportCN¥15.60
ResistanceCN¥18.98
MA 20CN¥17.29
MA 50CN¥16.57
MA 200CN¥13.73
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61

Valuation

Fair ValueCN¥4.29
Target PriceCN¥23.00
Upside/Downside28.42%
GradeOvervalued
TypeValue
Dividend Yield1.12%

Risk Assessment

Beta0.54
Volatility52.84%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.